Correlation of HTA Decision Outcomes in France and Germany von Sun, D, Beckerman, R, Bustamante, M.M.D

Volltext

PNS134 RE-SUBMISSIONS WITH RWE: CAN THEY HELP CHANGE YOUR BENEFIT RATING? von Bolton, W., Rusher, K., Bustamante, M.M.D.

Volltext

PRO99 EVALUATING THE HTA IMPACT OF REAL-WORLD EVIDENCE FROM FORMAL ORPHAN DRUG REGISTRIES von Bustamante, M.M.D., Yang, E., Anderson, K.

Volltext

PCN376 ACCESS TO ONCOLOGY THERAPIES IN RUSSIA AND VISEGRAD GROUP COUNTRIES von Subbotina, E., Walker, W., Bustamante, M.M.D.

Volltext

PCN224 THE RISING PATIENT VOICE: CHANGING VALUE OF PRO & QOL METRICS von Bustamante, M.M.D., Shah, S., Mirabella, M.

Volltext

PCN221 OCM TO OCF: IMPLICATIONS FOR TOTAL COST OF CARE von Bustamante, M.M.D., Yang, E., Katz, S., Badillo, A.

Volltext

PCN228 THE IMPORTANCE OF THE OVERALL SURVIVAL ENDPOINT IN EU HTA DECISION-MAKING von Bustamante, M.M.D., Oshinowo, B., Subbotina, E., McGahan, S.

Volltext

PCN188 THE IMPORTANCE OF OVERALL SURVIVAL AS A CLINICAL ENDPOINT IN FDA VS EMA REGULATORY APPROVAL von Bustamante, M.M.D., Oshinowo, B., Subbotina, E., McGahan, S.

Volltext

PCN192 - Correlation of HTA Decision Outcomes in France and Germany von Sun, D., Beckerman, R., Bustamante, M.M.D.

Volltext